PURPOSE: The aim of this study was to report the 5-year results of accelerated partial breast irradiation (APBI) using external beam three-dimensional conformal radiotherapy (3D-CRT). PATIENTS AND METHODS: Between 2006 and 2011, 44 patients with low-risk, stage I-II breast cancer underwent breast-conserving surgery. Postoperative APBI was given by means of 3D-CRT using three to five non-coplanar fields. The total dose of APBI was 36.9 Gy (nine fractions of 4.1 Gy b.i.d.). The mean follow-up time was 58.2 months for surviving patients. Survival results, side effects, and cosmetic results were assessed. RESULTS: One (2.3%) local recurrence was observed, for a 5-year actuarial rate of 3.7%. Neither regional nor distant failure was observed. Two patients died of internal disease. The 5-year disease-free, cancer-specific, and overall survival rates were 96.3, 100, and 95.1%, respectively. Acute side effects included grade 1 (G1) erythema in 75%, G1 parenchymal induration in 46%, and G1 pain in 46% of patients. No G2 or higher acute side effect occurred. Late side effects included G1, G2, and G3 fibrosis in 44, 7, and 2% of patients, respectively, G1 skin pigmentation in 12%, and G1 pain in 2%. Asymptomatic fat necrosis occurred in 14%. Cosmetic results were rated excellent or good in 86% of cases by the patients themselves and 84% by the physicians. CONCLUSIONS: The 5-year local tumor control, toxicity profile, and cosmetic results of APBI delivered with external beam 3D-CRT are encouraging and comparable to other APBI series.
PURPOSE: The aim of this study was to report the 5-year results of accelerated partial breast irradiation (APBI) using external beam three-dimensional conformal radiotherapy (3D-CRT). PATIENTS AND METHODS: Between 2006 and 2011, 44 patients with low-risk, stage I-II breast cancer underwent breast-conserving surgery. Postoperative APBI was given by means of 3D-CRT using three to five non-coplanar fields. The total dose of APBI was 36.9 Gy (nine fractions of 4.1 Gy b.i.d.). The mean follow-up time was 58.2 months for surviving patients. Survival results, side effects, and cosmetic results were assessed. RESULTS: One (2.3%) local recurrence was observed, for a 5-year actuarial rate of 3.7%. Neither regional nor distant failure was observed. Two patients died of internal disease. The 5-year disease-free, cancer-specific, and overall survival rates were 96.3, 100, and 95.1%, respectively. Acute side effects included grade 1 (G1) erythema in 75%, G1 parenchymal induration in 46%, and G1 pain in 46% of patients. No G2 or higher acute side effect occurred. Late side effects included G1, G2, and G3 fibrosis in 44, 7, and 2% of patients, respectively, G1 skin pigmentation in 12%, and G1 pain in 2%. Asymptomatic fat necrosis occurred in 14%. Cosmetic results were rated excellent or good in 86% of cases by the patients themselves and 84% by the physicians. CONCLUSIONS: The 5-year local tumor control, toxicity profile, and cosmetic results of APBI delivered with external beam 3D-CRT are encouraging and comparable to other APBI series.
Authors: Tanya S Berrang; Ivo Olivotto; Do-Hoon Kim; Alan Nichol; B C John Cho; Islam G Mohamed; Tarnjit Parhar; J R Wright; Pauline Truong; Scott Tyldesley; Jonathan Sussman; Elaine Wai; Tim Whelan Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-23 Impact factor: 7.038
Authors: Alan A Lewin; Robert Derhagopian; Kunal Saigal; Joseph E Panoff; Andre Abitbol; D Jay Wieczorek; Vivek Mishra; Isildinha Reis; Annapoorna Ferrell; Lourdes Moreno; Cristiane Takita Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-02 Impact factor: 7.038
Authors: Ivo A Olivotto; Timothy J Whelan; Sameer Parpia; Do-Hoon Kim; Tanya Berrang; Pauline T Truong; Iwa Kong; Brandy Cochrane; Alan Nichol; Isabelle Roy; Isabelle Germain; Mohamed Akra; Melanie Reed; Anthony Fyles; Theresa Trotter; Francisco Perera; Wayne Beckham; Mark N Levine; Jim A Julian Journal: J Clin Oncol Date: 2013-07-08 Impact factor: 44.544
Authors: Csaba Polgár; Tibor Major; János Fodor; Zoltán Sulyok; András Somogyi; Katalin Lövey; György Németh; Miklós Kásler Journal: Radiother Oncol Date: 2010-02-22 Impact factor: 6.280
Authors: Grace L Smith; Ying Xu; Thomas A Buchholz; Sharon H Giordano; Jing Jiang; Ya-Chen Tina Shih; Benjamin D Smith Journal: JAMA Date: 2012-05-02 Impact factor: 56.272
Authors: Reshma Jagsi; Merav A Ben-David; Jean M Moran; Robin B Marsh; Kent A Griffith; James A Hayman; Lori J Pierce Journal: Int J Radiat Oncol Biol Phys Date: 2010-01-01 Impact factor: 7.038
Authors: Kara Lynne Leonard; Jaroslaw T Hepel; Jessica R Hiatt; Thomas A Dipetrillo; Lori Lyn Price; David E Wazer Journal: Int J Radiat Oncol Biol Phys Date: 2012-08-04 Impact factor: 7.038
Authors: Benjamin D Smith; Douglas W Arthur; Thomas A Buchholz; Bruce G Haffty; Carol A Hahn; Patricia H Hardenbergh; Thomas B Julian; Lawrence B Marks; Dorin A Todor; Frank A Vicini; Timothy J Whelan; Julia White; Jennifer Y Wo; Jay R Harris Journal: Int J Radiat Oncol Biol Phys Date: 2009-07-15 Impact factor: 7.038
Authors: Janet K Horton; Rachel C Blitzblau; Sua Yoo; Joseph Geradts; Zheng Chang; Jay A Baker; Gregory S Georgiade; Wei Chen; Sharareh Siamakpour-Reihani; Chunhao Wang; Gloria Broadwater; Jeff Groth; Manisha Palta; Mark Dewhirst; William T Barry; Eileen A Duffy; Jen-Tsan A Chi; E Shelley Hwang Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-14 Impact factor: 7.038
Authors: Norbert Mészáros; Tibor Major; Gábor Stelczer; Levente Jánváry; Zoltán Zaka; Dávid Pukancsik; Zoltán Takácsi-Nagy; János Fodor Md; Csaba Polgár Journal: Breast Date: 2020-10-30 Impact factor: 4.380
Authors: X Li; J Sanz; N Argudo; M Vernet-Tomas; N Rodríguez; L Torrent; E Fernández-Velilla; O Pera; Y Huang; P Nicolau; M Jiménez; M Segura; M Algara Journal: Clin Transl Oncol Date: 2021-11-18 Impact factor: 3.405